Zynlonta

Chemical Nameloncastuximab tesirine-lpyl
Dosage FormInjection (intravenous; 10 mg of loncastuximab tesirine-lpyl as a lyophilized powder in a single-dose vial for reconstitution and further dilution)
Drug ClassMonoclonal antibodies
SystemBlood
CompanyADC Therapeutics America
Approval Year2021

Indication

  • Indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, and high-grade B-cell lymphoma.
Last updated on 4/30/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Zynlonta (loncastuximab tesirine-lpyl ) Prescribing Information2021ADC Therapeutics America, Murray Hill, New Jersey